Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Avigan Administered to Ebola-Infected French Woman: Fujifilm
September 29, 2014
- Sanofi’s 2013 Payments to Healthcare Professionals Down 11%
September 29, 2014
- Novartis Files Panobinostat for Multiple Myeloma in Japan
September 29, 2014
- Sanofi Opens Asia Pacific Development Hub in Shanghai
September 29, 2014
- Ribomic Goes Public, Aims to Swing to Black on Aptamers
September 26, 2014
- NBI Paid 14.6 Billion Yen to Healthcare Professionals in 2013
September 26, 2014
- Takeda to Invest 2.5 Billion Yen in US Firm for New Drug Development
September 26, 2014
- OncoTherapy Science Appoints Masaharu Mori, Formerly of Shionogi and Novartis Pharma, as New President
September 26, 2014
- Eisai Sets Up Director Position for Pariet
September 26, 2014
- US FDA Accepts NDA for Abilify Successor Brexpiprazole: Otsuka, Lundbeck
September 26, 2014
- AZ Managed to Speed Up Pilot R&D Projects under New Structure: President
September 25, 2014
- MSD Paid 19.4 Billion Yen to Healthcare Professionals in 2013
September 25, 2014
- Gilead Sciences Submits NDA for Ledipasvir/Sofosbuvir Combination for Genotype 1 Chronic Hepatitis C
September 25, 2014
- AnGes MG to Start Collategene Administration in PIII Study in US as Early as October
September 25, 2014
- Ibandronate Oral Agent to Be Filed for Japan Approval in 2015: Chugai, Taisho
September 24, 2014
- Meiji Seika Pharma Seeks New Indication for Laserphyrin
September 24, 2014
- Mediceo Sets to Increase Qualified Reps to 2,000, Enter Contract PMS Biz within 3 Years
September 22, 2014
- Bristol-Myers Submits NDA for Malignant Melanoma Drug Ipilimumab
September 22, 2014
- Additional Indication Approved for MTPC’s Telavic
September 22, 2014
- RaQualia Wins Use-Patent Allowance for EP4 Antagonist in US
September 22, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…